A novel ursodeoxycholic acid derivative exhibits broad-spectrum antiviral activity against influenza A virus and coronaviruses by multiphasic disruption of the viral life cycle
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.00284-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Zheng Peng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of New Drug Screening, Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutica…. Hauptthemen laut MEDLINE: Antiviral Agents, Ursodeoxycholic Acid, Influenza A Virus, H3N2 Subtype, Influenza A Virus, H1N1 Subtype. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Major scientific and technological projects of Guangdong Province, National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Seasonal influenza virus and human coronaviruses (HCoVs) represent persistent threats to global public health, with current antiviral agents limited by narrow-spectrum activity and the emergence of drug resistance. Multi-stage and multi-target antiviral agents enhance therapeutic efficacy and overcome drug resistance versus single-target therapies by inhibiting multiple key steps of the viral life cycle, such as entry, replication, and release. Here, we characterize a novel ursodeoxycholic acid (UCDA) derivative (U-BSA) as a broad-spectrum antiviral candidate effective against influenza A viruses (H1N1 and H3N2), HCoVs (including HCoV-OC43 and other pseudovirus models), and respiratory syncytial virus (RSV). In vitro , U-BSA exhibited inhibitory activity against H1N1 (half-maximal effective concentration [EC 50 ] = 4.10 µM; selectivity index [SI] > 50), H3N2 (EC 50 = 2.41 µM, SI > 40), HCoV-OC43 (EC₅₀ = 9.66 µM, SI > 20), and RSV (EC 50 = 6.01 µM, SI > 12). Furthermore, U-BSA conferred significant protection in a lethal influenza infection model in vivo . Mechanistic studies demonstrated that U-BSA interferes with multiple viral life cycles: it disrupts viral attachment, inhibits entry by blocking endosomal acidification, and suppresses virion release. U-BSA rescues virus-induced membrane lipid disorder, revealing that modulation of host membrane homeostasis serves as a critical upstream mechanism underlying its multiphasic antiviral inhibition. This multi-target mode of action represents a significant advance in antiviral strategy, highlighting U-BSA as a promising candidate for developing broad-spectrum antivirals against pan-respiratory virus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of New Drug Screening, Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
- Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, China.
- Key Laboratory for Biobased Materials and Energy of Ministry of Education, College of Materials and Energy, South China Agricultural University, Guangzhou, China.
- NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Department of Pharmacy, Pingshan Hospital, Southern Medical University, Shenzhen, China.
- State Key Laboratory of Multi-organ Injury Prevention and Treatment, MOE Key Laboratory of Infectious Diseases Research in South China, MOE Innovation Center for Medical Basic Research on Inflammation and Immune Related…
ORCID-Profile: Zheng Peng, Gaopeng Song, Shuwen Liu
Förderung
- Major scientific and technological projects of Guangdong Province
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Post Scientist Fund awarded by Chinese Academy of Traditional Chinese Medicine
Zitieren
APA
Peng, Z., Yuan, H., Huang, J., Lin, X., Yang, C., Song, G., & Liu, S. (2026). A novel ursodeoxycholic acid derivative exhibits broad-spectrum antiviral activity against influenza A virus and coronaviruses by multiphasic disruption of the viral life cycle. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00284-26
Vancouver
Peng Z, Yuan H, Huang J, Lin X, Yang C, Song G, et al. A novel ursodeoxycholic acid derivative exhibits broad-spectrum antiviral activity against influenza A virus and coronaviruses by multiphasic disruption of the viral life cycle. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00284-26
BibTeX
@article{Peng2026,
author = {Peng, Zheng and Yuan, Haoxing and Huang, Junran and Lin, Xinxin and Yang, Chan and Song, Gaopeng and Liu, Shuwen},
title = {A novel ursodeoxycholic acid derivative exhibits broad-spectrum antiviral activity against influenza A virus and coronaviruses by multiphasic disruption of the viral life cycle},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.00284-26}
}
EUVIMED